IMPORTANCE Biotinylated antibodies and analogues, with their strong binding to streptavidin, are used in many clinical laboratory tests. Excess biotin in blood due to supplemental biotin ingestion may affect biotin-streptavidin binding, leading to potential clinical misinterpretation. However, the degree of interference remains undefined in healthy adults.
Excessive biotin in a blood sample can compete with biotinylated components in the assay, potentially falsely decreasing results in sandwich immunoassays or falsely increasing results in competitive immunoassays (eFigures 1 and 2 in the Supplement).
14 Due to a lack of systematic studies, little is known about whether or how performance of specific biotinylated immunoassays may be associated with biotin ingestion at doses common in over-the-counter supplements (10 mg/d) in healthy adults. Therefore, this study was designed to assess the association of short-term biotin ingestion for 7 days with performance of assays that measure 11 hormone and nonhormone analytes: thyroid-stimulating hormone (TSH), total thyroxine (T4), total triiodothyronine (T3), free T4, free T3, intact parathyroid hormone (PTH), prolactin, N-terminal pro-brain natriuretic peptide (NT-proBNP), 25-hydroxyvitamin D (25-OHD) in 6 healthy adults, and ferritin and prostate-specific antigen (PSA) in the 4 men, using 4 assay systems.
Methods

Study Design
This study was approved by the institutional review board at the University of Minnesota. Six healthy adults responded to study announcement fliers, gave informed consent before participation, and were not compensated. Exclusion criteria including but not limited to conditions that potentially affect biotin or hormones were being pregnant or lactating, having known thyroid disease, undergoing thyroid hormone treatment, ingesting over-the-counter dietary or nutritional supplements (excluding standard multivitamin preparations containing no more than 100% of the daily value for biotin and calcium), working the night shift, smoking, 15 being treated with anticonvulsant medicine, 16 or lacking the capacity to consent. Participants were asked to stop taking multivitamins 2 weeks before study participation.
Intervention
Participants were instructed to take 10 mg/d of biotin (Nature Made) at the same time each morning for 7 days. Blood specimens were collected by venipuncture at baseline prior to starting biotin, after 1 week of biotin supplementation (day 7), and 1 week after participants stopped taking biotin (day 14). On the last day of treatment (day 7), the blood specimen was drawn approximately 2 hours after taking their last dose. Blood specimens were labeled with participant study identification number and date, promptly centrifuged and processed to produce serum sample aliquots that were stored up to a year at −70°C until further analysis.
Outcomes
Eighteen serum samples, collected from the 6 participants at the 3 time points, were each split into 4 aliquots and sent for testing at 4 clinical laboratories using different diagnostic assay systems: Johns Hopkins Medical Institutions used Roche cobas e602 for measurement of all 9 hormones and ferritin; Children's Mercy Hospital used the OCD Vitros 5600 for TSH, PTH, total T4, total T3, free T4, NT-proBNP, and ferritin and Siemens Immulite 2000 for prolactin. The University of Minnesota Medical Center used Siemens Vista Dimension 1500 for TSH, PTH, total T4, free T4, free T3, NT-proBNP, ferritin, and PSA and Siemens Advia Centaur XP for total T3 and PTH; Boston Medical Center used Abbott Architect 2000 for TSH, PTH, total T4, total T3, free T4, prolactin, 25-OHD, ferritin, and PSA. eTable 1 in the Supplement summarizes information on the 37 assays for the 11 analytes evaluated on 4 systems: 23 incorporated biotin and streptavidin components and 14 did not include those components, serving as negative controls. Analytical imprecision data for these 37 assays are included in eTable 2 in the Supplement. Two immunoassay principals were used (eFigures 1 and 2 in the Supplement): the sandwich immunoassay for TSH, PTH, prolactin, NT-proBNP, PSA, and ferritin and the competitive immunoassay for total T4, total T3, free T4, free T3, and 25-OHD. Four analytes (NT-proBNP, ferritin, 25-OHD, and PSA) were performed as a second tier after the initial analysis of 7 analytes (TSH, intact PTH, total T4, total T3, free T4, free T3, prolactin). As a result, the sample size for some tests was less than 6 due to an insufficient volume in the blood sample or sex differences in the reference range. Prostate-specific antigen and ferritin were measured for only the 4 men.
Key Points
Question Does oral biotin supplementation interfere with hormone and nonhormone assays that use biotinylation in their design?
Findings In this nonrandomized crossover study of 6 healthy adults (2 women, 4 men), 10 mg/d of biotin ingested for 1 week was associated with potentially clinically important assay interferences in some but not all biotinylated hormone and nonhormone assays studied.
Meaning Oral biotin use may be associated with false hormone and nonhormone assay results. Assays were performed for each analyte as a single batch, on automated systems, by clinical laboratory technologists blinded to the nature of the study. Serum biotin was measured by the Cambridge Biomedical Research Group (Boston, Massachusetts) using a microbial growth assay.
17 Serum calcium was measured at Johns Hopkins Medical Institutions with the Roche cobas c701 chemistry analyzer.
Statistical Analysis
The study was powered to detect changes larger than the expected assay coefficient of variations (imprecisions) at normal reference levels for common hormone tests (eTable 2 in the Supplement). Because significant biotin ingestionassociated changes were observed in some assays studied, study recruitment was terminated after data analysis from the first 6 participants. Analyte levels below or above their reportable ranges were assigned the following values: for Ortho Vitros NT-proBNP, 11 pg/mL was used for levels reported to be lower than 11.1 pg/mL; for both Siemens Vista Dimension and Roche cobas NT-proBNP, 4 pg/mL was used for levels reported that were less than 5 pg/mL. For biotin more than 3600 ng/mL, 3601 ng/mL was used. These value assignments would underestimate any biotin interference that was present. (To convert biotin from pg/mL to nmol/L, multiply by 0.00409; prolactin from ng/mL to pmol/L, multiply by 43.478; free T3 from pg/mL to pmol/L, multiply by 1.54; total T3 from ng/mL to nmol/L, multiply by 1.54; free T4 from ng/dL to pmol/L, multiply by 12.871; total T4 from μg/dL to nmol/L, multiply by 12.871.)
Each combination of an analyte and a system was analyzed separately with repeated measures of an analysis of variance (ANOVA) (mixed linear model), for which the random effect was a participant and the within-participant fixed effect was time (day of study). The primary analysis compared study day 7, the last day participants took biotin, with the mean of baseline and study day 14, before participants took biotin and after they stopped taking biotin, using a contrast in the ANOVA. a Each analysis was a repeated measures analysis of variance (ANOVA; mixed linear model), for which the random effect was a participant and the within-participant fixed effect was time. The primary comparison was study day 7 vs the mean of the baseline and study day 14 using a contrast in the ANOVA, ie: study day 7 −(½ baseline + study day 14). Data are presented as the absolute mean difference of study day 7 from the mean of baseline and study day 14. The units for the study day-7 difference are the same as those of analyte concentrations.
b Calcium values were included because they are necessary to interpret parathyroid hormone results. To test this contrast for each analyte and system, P < .05 was the criterion for statistical significance. For each combination of an analyte and a system, we also present comparisons of pairs of times using the Tukey honest significant difference post hoc test. Data are reported as mean and 95% CIs. The Fisher exact test was used to compare biotin interference outcomes between the biotinylated assays and nonbiotinylated assays. All tests were 2-sided. All analyses used JMP Pro v13 (SAS Institute Inc).
Results
Characteristics of the Study Population
Six healthy adults enrolled in the study, 2 women and 4 men, with a mean age of 38 years (range, 31-45 years). Baseline analyte concentrations for the 6 participants were within the manufacturer's reference ranges for 7 analytes measured by 29 assays, except for 4 analytes measured by 8 assays: (1) PTH by OCD Vitros 5600 and Siemens Advia Centaur XP; (2) total T4 by Abbott Architect; (3) prolactin by Roche cobas e602, Siemens Immulite 2000, and Abbott Architect; and (4) ferritin by the Roche cobas e602 and Abbott Architect. In each case, this involved no more than 1 or 2 participants. None of the participants had abnormal baseline results across all systems for a given analyte.
Biotin Ingestion and Assay Performance
The mean baseline serum biotin concentration was 774 pg/mL (95% CI, 554-1004 pg/mL) compared with a mean study day-7 concentration of more than 3600 pg/mL (95% CI, 3601-3601, mg/mL; P value <.001) for all 6 participants ( Figure 1A ). On study day 14, the mean biotin concentration decreased to Abbreviations: See Figure legends for full names of the assay systems.
SI conversion factors: To convert total T3 from ng/mL to nmol/L, multiply by 1.54; total T4 from μg/dL to nmol/L, multiply by 12.871; free T3 from pg/mL to pmol/L, multiply by 1.54; free T4 from ng/dL to pmol/L, multiply by 12.871.
a Each analysis was a repeated measures of analysis of variance (ANOVA; mixed linear model), for which the random effect was a participant and the within-participant fixed effect was the study day. The primary comparison was study 7 vs the mean of the baseline and study day 14 measures using a contrast in the ANOVA, ie: study day 7 −(½ baseline + day 14). Data are presented as the absolute mean difference of day 7 from the mean of baseline and day 14 (95% CI). The units for the day 7 difference are the same as those of analyte concentrations.
1090 pg/mL (95% CI, 687-1493 pg/mL). Baseline and study day 14 biotin concentrations did not differ statistically (eTable 4 in the Supplement).
Biotin ingestion was associated with falsely decreased Roche cobas e602 TSH levels by a mean of 0.72 mIU/L (95% CI, −1.13 to −0.32 mIU/L; P = .006), a 37% reduction from baseline, although all results remained within the euthyroid reference range ( Figure 1B ). The interference was much greater when measured by the Vitros 5600 TSH assay ( Figure 1C ) for which TSH significantly decreased by a mean of 1.67 mIU/L (95% CI, −2.08 to −1.26 mIU/L; P < .001), a 94% reduction from baseline, with all results falsely decreased to below the reference range (ie, <0.15 mIU/L; reference range, 0.47-4.68 mIU/L).
Biotin ingestion was associated with significantly decreased OCD Vitros PTH results by a mean of 25.8 pg/mL (95% CI, −34.8 to −16.8 pg/mL; P < .001), a 61% reduction from baseline. In 2 participants with normal baseline PTH concentrations, biotin ingestion was associated with falsely decreased PTH results, slightly below the lower limit of the reference range at 7.0 pg/mL and 7.2 pg/mL (reference range, 7.5-53.5 pg/mL). Serum calcium concentrations in all participants remained stable within the reference range ( Table 1) .
Biotin ingestion was associated with statistically significant false increases in 4 assays: 3 Roche cobas e602 assays measuring total T3, free T3, and free T4; and the Siemens Vista Dimension 1500 measuring free T3 (Figure 2 and Figure 3 ). Roche cobas e602 total T3 concentrations falsely increased by a mean of 0.85 ng/mL (95% CI, 0.49-1.22 ng/mL; P = .001), whereas Siemens Vista free T3 concentration falsely increased by a mean of 0.78 pg/mL (95% CI, 0.50-1.06 pg/mL; P < .001; Table 2 ). In 3 participants, the Roche cobas e602 total T3 results and in 1 participant Siemens Vista free T3 result were higher than their respective reference ranges. Table 3 shows the results for prolactin, which did not have biotin-associated changes.
eFigure 3 in the Supplement shows that biotin ingestion was associated with falsely reduced OCD Vitros 5600 NT-proBNP results by an average of more than 13.9 pg/mL (95% CI, −24.7 to −3.12 pg/mL; P = .03) to less than 11.1 pg/mL in all participants. The actual reduction was underestimated because results while participants were taking biotin were below the assay's reportable range. Biotin ingestion was associated with falsely increased Roche cobas 25-OHD results by a mean of 9.25 ng/mL (95% CI, 5.72-12.8 ng/mL; P < .001) higher than the baseline (eTable 3 in the Supplement). None of the 11 analytes measured by 37 assays differed between baseline and day 14, except ferritin measured by the Siemens Vista Dimension (eTable 4 in the Supplement). Ferritin at day 7 of biotin treatment did not differ significantly from the mean of baseline and day 14 or from baseline alone in all 4 systems, supporting that biotin ingestion was not associated with the difference between baseline and day 14.
Biotin interference was not observed in any of the 14 nonbiotinylated assays (Table 4) . Biotin interference was not observed in 14 of the 23 (61%) biotinylated assays; however, it was observed in 9 of the 23 (39%) biotinylated assays: falsely decreasing results in 4 sandwich immunoassays (4 of 15 [27%]); falsely increasing results in 5 competitive immunoassays (5 of 8 [63%]). Biotin interference outcomes were significantly different between biotinylated assays (9 of 23 [39%]) and nonbiotinylated assays (none) (Fisher exact test, P = .007).
Discussion
This study involving 6 healthy adults demonstrated that oral biotin was associated with potentially clinically important assay interference in some but not all biotinylated assays. Among the 23 biotinylated assays studied, biotin interference was of greatest clinical significance in the OCD Vitros TSH assay, where falsely decreased TSH concentrations (to <0.15 mU/L) could have resulted in misdiagnosis of thyrotoxicosis in otherwise euthyroid individuals. Likewise, falsely decreased OCD Vitros NT-proBNP, to lower than assay detection limits, could possibly result in failure to identify congestive heart failure. 18 Because healthy study participants had normal baseline NT-proBNP, further study of patients with high baseline NT-proBNP concentration would be required to establish the effect of biotin interference on the diagnosis of heart failure. The smaller changes observed in other assays, namely OCD Vitros PTH; Roche cobas e602 TSH, total and free T3, free T4, and 25-OHD; and Siemens Vista free T3, although primarily producing false results within the reference range among participants while taking biotin, could lead to falsely normal or abnormal interpretation of the results for individuals starting from baseline levels closer to the reference range limits.
19
Many of the studied biotinylated assays were not affected by 7 days of biotin, despite what would have been predicted (Table 4) based on the assay biotin and streptavidin components. For some assays (eg, Roche cobas e602 PTH, total T4, free T4, and prolactin and Siemens Vista 1500 TSH, PTH, free T4, and prolactin), there are reports of biotin interference. [20] [21] [22] [23] [24] For example, a falsely low Roche Elecsys PTH level of 48 ng/L was reported in a patient with hyperparathyroidism in chronic kidney disease (true PTH level 576 ng/L).
21
Potential reasons for discrepancies between predicted and actual biotin interference in an individual blood sample include inherent differential biotin interference tolerance among biotinylated assays owing to assay design, endogenous levels of free biotin and biotin metabolites present in the sample, 21, 25, 26 the type of biotin supplement, the dose and duration of biotin ingestion, 20 time of blood draws after the last dose, and the analyte concentration. Supraphysiologic doses of biotin may increase blood concentrations by 1.5 to 163 times higher than normal, depending on dose and measurement time after administration. 20, 21, [27] [28] [29] Differential biotin interference tolerance among assays is likely due to the amounts of biotinylated antibodies or analogues used, the availability of streptavidin binding sites and areas in the assay reagents (eg, streptavidin-coated magnetic particles) (eFigures 1 and 2 in the Supplement), and possible effects from biotin metabolites. The time required for patients to stop taking supplements with biotin to avoid assay interference appears to be variable and may depend on the patient population, time of blood collection relative to the last biotin dose, biotin dose, chronicity of biotin exposure, and half-life of free biotin and biotin metabolites in plasma. Maximal assay interference was demonstrated 2 hours after a single 30-mg biotin dose. 30 Peak biotin blood concentration occurred 1.25 hours and 1.5 hours after a 100-mg and a 300-mg single dose, respectively, with half-life up to 18.8 hours following a single 300-mg dose. 28 In contrast, a 1.8-hour half-life was reported from a 600-μg biotin dose. 31 Biotin metabolite concentrations (ie, bisnorbiotin) were significantly higher following months of taking 100 mg of biotin 3 times a day than they were following a single 300-mg dose, 20 Falsely abnormal hormone levels returned to normal 3 days after ceasing to take 300 mg of biotin in 3 daily doses and 2 days after ceasing to take up to 300 mg of biotin. 34, 35 In pediatric populations, biotin interference was found 2 days after the last dose of biotin (10 mg/d for 4 days), and disappeared at a week in infants and young children receiving between 2 and 15 mg/kg/d. 32, 36 In the current study, mean biotin concentration returned to baseline and the biotin ingestion-associated interferences resolved 1 week after a 10-mg/d 7-day course.
20
Limitations
To our knowledge, the current study is the first to systematically assess the association of biotin ingestion (10 mg/d for 7 days) in healthy adults with performance of 37 assays that measure 11 analytes over 4 major diagnostic systems (Table 4) . The study has several limitations. First, only healthy adults with mostly normal analyte concentrations were evaluated. Second, the study was neither randomized nor blinded to the investigators or participants, although it was blinded to the clinical laboratories. The study did not have a placebo group, but the crossover design and repeated measures analysis allowed each participant's baseline values to serve as his/her own controls, making it more efficient (smaller sample size is needed) than a randomized design, because between-person variability in overall level of an analyte is eliminated. Third, because no formal dose-response pharmacokinetic study of biotin at various doses was performed, the minimal dose and duration required to alter assay results remains undetermined. Fourth, the sample size was small; power may have been insufficient to detect smaller effects of biotin ingestion. Definitive studies of the effect of biotin on specific assays and analytes will require further investigation. Despite these limitations, this study reinforces cautionary advice regarding potential limitations of assays that use biotin streptavidin binding for clinical evaluation of individuals who ingest large doses of biotin. A few assay manufacturers package inserts acknowledge biotin interference, recommending delayed sample collection after biotin intake. Based on these findings, manufacturers may need to consider modifying biotinylated assays to minimize the effects of biotin ingestion. 
Conclusions
In this preliminary study of 6 healthy adult participants and 11 hormone and nonhormone analytes measured by 37 immunoassays, ingesting 10 mg/d of oral biotin for 1 week was associated with potentially clinically important assay interference in some but not all biotinylated assays studied. These findings should be considered for patients taking biotin supplements before ordering blood tests or when interpreting results. 
Supplement eFigure 2. Principle of the Roche cobas e602 competitive immunoassay for Total T4 in a blood sample (A and B) and effect of excess biotin in a blood sample (C).
(A). Total T4, released from binding proteins, forms a T4 immuno-ruthenium complex with ruthenium labeled anti-T4 monoclonal antibody; (B). Streptavidin-coated magnetic particles and a fixed amount of biotinylated T4 are then added; T4 from the blood sample competes with the added biotinylated T4 for binding the unoccupied ruthenium anti-T4 monoclonal antibody. Biotinylated T4 complexes (both ruthenium bound and unbound), are captured on the streptavidin-coated magnetic particles. Streptavidin-captured T4 immuno-ruthenium complexes have an inverse relationship to T4 from the blood sample; (C). Excessive biotin competes with biotinylated T4 for binding to the streptavidin-coated magnetic beads, and therefore decreases streptavidin captured T4 immuno-ruthenium complex. Because of the negative relationship between streptavidin-captured T4 immuno-ruthenium complex and the competitive assay's ruthenium signal readout, excessive biotin in a blood sample produces a falsely increased T4 result for the blood sample. Assays evaluated in the study are indicated by immunoassay format, type of analyte measured, manufacturer/analyzer, testing location, reference range as defined on the manufacturer's package insert for the assay, whether or not the assay has biotinylated components and the predicated effect and direction of biotin interference.
Abbreviations: TSH =thyroid stimulating hormone; PTH = parathyroid hormone; NT-ProBNP= N-terminal pro-brain natriuretic peptide; PSA=prostate specific antigen; total T4 = total thyroxine; Total T3 = total triiodothyronine; Free T4 = free thyroxine; Free T3= free triiodothyronine; 25-OHD= 25 hydroxyvitamin D, JHMI = Johns Hopkins Medical Institutions; CMH= Children's Mercy Hospital; UMMC= University of Minnesota Medical Center;
BMC= Boston Medical Center.
*Abbott Architect Quantia used a polyclonal antibody immuno-agglutination method.
To convert PTH pg/ml to ng/L, multiply by 1.
To convert prolactin ng/ml to pM, multiply by 43.478.
To convert NT-proBNP pg/ml to pM multiply by 0.118
To convert PSA ng/ml to mcg/L, multiply by 1
To convert ferritin ng/ml to pM, multiply by 2.247
To convert Total T4 mcg/dl to nM, multiply by 12.871. To convert Total T3 ng/ml to nM, multiply by Imprecision data are shown for assay systems and individual analytes including the quality control analyte concentration at which the precision analysis was performed (QC level), SD (standard deviation), and percent intra-assay coefficient of variation (%CV). 
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. 05 -20 (-8.0; 47) .15 7.8 (-20; 35) .68 27 (-0.2; 55) .05 .13 -32 (-9.7; 73) .12 -11 (-31; 52) .72 21 (-20; 62) .33 .02 -23 (-3.8; 50) .09 11 (-16; 38 Each analysis was a repeated measures ANOVA (mixed linear model) where the subject effect was a person and the within subject effect was time (day of study). The table shows comparisons of pairs of times using Tukey's HSD post hoc test. Least Squares (LS) mean difference data are derived from subtracting LS mean day 7 -0, day 7 -14, or day 0 -14. The units for each analyte difference are listed in column 1.
Vitros
Vista
All tests were performed on 6 participants, except PSA and ferritin, which were performed on 4 men; n=4 for all ferritin and PSA assays except n=3
for Abbott Architect ferritin and PSA, while n for all other tests is 6 except Architect 25-OHD (n=5).
The numerator degrees of freedom (DF) is 2 for all tests. The denominator DF is 4 for Architect PSA and ferritin, 6 for the other male-only tests, and 8 for Architect 25-OHD. For all other tests the denominator DF is 10.
Abbreviations: TSH =thyroid stimulating hormone; PTH = parathyroid hormone; NT-proBNP= N-terminal pro-brain natriuretic peptide; PSA=prostate specific antigen; Total T4 = total thyroxine; Total T3 = total triiodothyronine; Free T4 = Free thyroxine; Free T3 = Free triiodothyronine; 25-OHD= 25 hydroxyvitamin D.
To convert Total T4 mcg/dl to nM, multiply by 12.871.
To convert Total T3 ng/ml to nM, multiply by 1.54. To convert Free T4 ng/dl to pM, multiply by 12.871. To convert Free T3 pg/ml to pM, multiply by 1.54. To convert 25-OHD ng/ml to nM, multiply by 2.496
